Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 8:38:100867.
doi: 10.1016/j.lanepe.2024.100867. eCollection 2024 Mar.

RSV immunisation in infants: weighing the options

Felix Günther  1 , Frank G Sandmann  1
Affiliations

RSV immunisation in infants: weighing the options

Felix Günther et al. Lancet Reg Health Eur. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The Robert Koch Institute (RKI) received funding for a modelling project of RSV immunisation strategies in Germany from the Federal Joint Committee (grant number: 01VSF18015). FGS holds an honorary, non-remunerated role at the London School of Hygiene and Tropical Medicine (LSHTM). The views expressed in this Comment are exclusively those of the authors.

References

    1. Wildenbeest J.G., Billard M.N., Zuurbier R.P., et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341–353. - PMC - PubMed
    1. Li Y., Wang X., Blau D.M., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–2064. - PMC - PubMed
    1. Hodgson D., Wilkins N., van Leeuwen E., et al. Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Reg Health Eur. 2024;38:100829. doi: 10.1016/j.lanepe.2023.100829. - DOI - PMC - PubMed
    1. Getaneh A.M., Li X., Mao Z., et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries. Vaccine. 2023;41(9):1623–1631. - PubMed
    1. Li X., Hodgson D., Flaig J., et al. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. Value Health. 2023;26(4):508–518. - PubMed

LinkOut - more resources